Skip to main content

Table 6 Multivariate Analysis in neoadjuvantly treated patients with gastric cancer without AEG II, III (UICC 7th)

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

  

HR

95% CI

p

R

R0

1.00

 

0.001

 

R1/2

3.40

1.7-6.8

 

Clinical response

yes

1.00

 

0.021

 

no

10.30

1.4-75.5

 

MTHFR A1298C

AA

1.00

 

0.028

 

AC

2.80

1.3-5.9

 
 

CC

2.00

0.5-7.6

Â